N4-hydroxycytidine and derivatives and anti-viral uses related thereto
This disclosure relates to certain N4-hydroxycytidine derivatives, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections, such as Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), Chikungunya fever (CHIK), Ebola, Influenza, RSV, and Zika virus infection with the disclosed compounds.
1. A process for producing a compound, comprising
a) reacting uridine having hydroxyl groups at positions 2′, 3′, and 5′ with a compound to protect or esterify the hydroxyl groups at positions 2′ and 3′ of uridine thereby forming a first intermediate;
b) simultaneously or subsequent to step a), esterifying the hydroxyl group at position 5′ of the first intermediate to form a carboxylic acid ester as a second intermediate;
c) reacting the second intermediate with a 1,2, 4-triazole compound followed by reaction with a hydroxylamine moiety at position 4, thereby forming a third intermediate; and
d) optionally deprotecting the third intermediate.
2. The process of claim 1 , wherein the uridine having hydroxyl groups at positions 2′, 3′, and 5′ is reacted with acetone to protect the hydroxyl groups a positions 2′ and 3′ of uridine.
3. The process of claim 1 , wherein the hydroxyl group at position 5′ of the first intermediate is esterified to form an isobutyrate ester as the second intermediate.
4. The process of claim 3 , wherein the hydroxyl group at position 5′ of the first intermediate is esterified with 2-methylpropanoyl 2-methylpropanoate.
5. The process of claim 1 , wherein the third intermediate is deprotected.
6. A compound obtained by the process of claim 5 .
7. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound as claimed in claim 6 .
8. A product produced by the process of claim 1 .